Isotopic Radiolabeling of Crizotinib with Fluorine-18 for In Vivo Pet Imaging

Isotopic Radiolabeling of Crizotinib with Fluorine-18 for In Vivo Pet Imaging

Crizotinib is a tyrosine kinase inhibitor approved for the treatment of non-small-cell lung cancer, but it is inefficient on brain metastases. Crizotinib is a substrate of the P-glycoprotein, and non-invasive nuclear imaging can be used to assess the brain penetration of crizotinib. Positron emissio...

Full description

Bibliographic Details
Main Authors: Malvika Sardana, Louise Breuil, Sébastien Goutal, Maud Goislard, Mikhail Kondrashov, Etienne Marchal, Florent L. Besson, Christophe Dugave, Gail Wrigley, Anna C. Jonson, Bertrand Kuhnast, Magnus Schou, Nicolas Tournier, Charles S. Elmore, Fabien Caillé
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Pharmaceuticals
Subjects:
fluorine-18
radiolabeling
crizotinib
PET imaging
Online Access:https://www.mdpi.com/1424-8247/15/12/1568

Internet

https://www.mdpi.com/1424-8247/15/12/1568

Similar Items